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Short Communication
Effect of cx-hydroxyvitamin D3 on metastasis of rat ascites
hepatoma K-231
T. Sato, K. Takusagawa, N. Asoo. & K. Konno
Department ofInternal Medicine, The Research Institutefor Tuberculosis and Cancer, Tohoku University,
Sendai 980, Japan.
Ih,25-DihydroxyvitaminD3( a,25(OH)2D3) convert-
edintheliverfrom lax-hydroxyvitamin D3(ho(OH)D3)
(Fukushima et al., 1975) has been known to
function in target tissues in binding to a specific
cytosol receptor and transportation to the nucleus
(Brumbaugh & Haussler, 1975). Although it has
been reported that the growth of some tumour cells
is inhibited in vitro by Ix,25(OH)D3 (Colston et al.,
1981; Abe et al., 1981), its antitumour effect has
been more recently demonstrated in vivo (Sato et
al., 1982; Honma et al., 1983). lcx(OH)D3 might be
used as a new anticancer agent with a mode of
action different from those currently used.
The purpose of this experiment was to examine
the effect of lcx(OH)D3 in vivo on metastases and
survival time of tumour-bearing rats.
Animals used were 9- to 12-week old male
ACI/N rats. The neoplasm was the ascites
hepatoma K-231 which was poorly differentiated
and rapidly growing (Sato & Sato, 1983). Animals
were given water and standard rat chow ad libitum.
After 106 tumour cells were transplanted s.c. into
the right posterior dorsum of rats, they were divided
at random into two groups which were
administered vehicle and It(OH)D3, respectively.
lx(OH)D3 (Chugai Pharmaceutical Co., Ltd.,
Tokyo) dissolved in medium chain triglyceride
(ODO®) (Nishin Oil Mills, Ltd., Tokyo) was
administered at a dose of 0.5 igkg-' into the
stomach by a stomach tube daily from a day after
inoculation to a day before killing. The animals
were killed on Day 13, and primary tumour and
right inguinal lymph node were weighed and the
number of macroscopically visible metastases on
the pulmonary surfaces counted. The survival times
of rats bearing tumour treated consecutively for 22
days from a day after inoculation were also
determined.
In a separate experiment the animals were
inoculated i.m. with 2 x 105 cells into the right hind
leg and were given the agents daily to a day before
killing as above-mentioned. The animals were killed
on Day 20 and metastases of lymph nodes and
lungs were also examined.
The tumour tissues were fixed in 10% formalin
solution and paraffin sections were stained with
H & E.
For testing the significance of the differences
between two groups the U-test, which is a ranking
test used for comparison when distribution is not
normal and variances are large, was used.
The primary tumour weight of rats treated with
1lo(OH)D3 was slightly reduced, but metastases of
lungs and right inguinal lymph nodes were
significantly inhibited (Table I & Figure 1).
Moreover, the prolongation of the life span of rats
bearing tumour treated with 1a(OH)D3 was slight,
but significantly different from the ODO group
(Figure 2).
In the i.m. implantation experiment because
bilateral lumbar lymph nodes were enlarged and
fused into one and invaded the retroperitoneum, on
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Figure 1 Metastases of right inguinal lymph nodes 13
days after s.c. inoculation. Lymph nodes of lx(OH)D3
group were evidently smaller than those of the control
ODO group. Bar= 10mm.
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Table I Effect of treatment with la(OH)D3 on ascites hepatoma
K-231 after s.c. implantation
Effective Primary Inguinal No. of
number tumour lymph node pulmonary
Group ofrats' wt (g) wt (g) metastases
ODO
treatment 6 5.52+0.67 0.76+0.31 8.7+1.8
lo(OH)D3
treatment 5 4.93+0.81 0.15+0.04b 3.2+ 1.9b
Values are the mean + s.e.
aAlthough the initial number of rats was 6 in each group, one
animals died inadvertently.
bSignificantly different, P<0.05.
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Figure 2 Percent survival of rats bearing tumour.
Seven rats in each group were inoculated s.c. with 106
K-231 ascites hepatoma cells and were given la(OH)
D3 (0.5ugkg-1) or vehicle (ODO®) daily for 22 days
from one day after tumour inoculation. The mean
survival times were 27.1 +0.8 days in the lo(OH)D3
group (---) and 24.8 +0.8 days in the ODO group
), respectively (P<0.05).
account of the delay before killing, they could not
be quantitatively estimated. However, primary
tumours and lumbar lymph nodes were not macro-
scopically different between both groups. The
weight of right inguinal lymph nodes was slightly
reduced, and the number of metastases to the lungs
was significantly decreased in the lae(OH)D3 group
(Table II).
Histologically, morphological changes in primary
tumour and metastatic lesions were not found
between the ODO and loe(OH)D3 groups (Figure 3).
These experiments demonstrated that lae(OH)D3
reduced the formation and development of
metastases in the lungs and lymph nodes more than
the growth of the primary tumour. Moreover it
prolonged the survival time of rats bearing tumour
for a few days (statistically significant). Since
la,25(OH)D3 receptors in certain human cancer cell
lines are commonly present, despite variability in
receptor concentration (Frampton et al., 1982)
Table II Effect of treatment with la(OH)D3 on ascites
hepatoma K-231 after i.m. implantation
Effective Inguinal No. of
number lymph node pulmonary
Group ofrats' wt (g)b metastases
ODO
treatment 5 0.30+0.07 45.2+ 17.5
la(OH)D3
treatment 6 0.25+0.09 14.8+ 3.5c
Values are the mean + s.e.
'Although the initial number of rats was 6 in each
group, one animal died inadvertently.
'The difference in lymph node wts between control
groups (Tables I and II) might be due to differences in the
site ofinjection and the number of tumour cells used.
cSignificantly different, P<0.05.
Figure 3 Histology of inguinal lymph node metastasis
in the la(OH)D3 group. No morphological difference
was found between this and the ODO groups. H & E.
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lk(OH)D3 might be useful in adjuvant therapy for
prevention of metastases of human tumours.
It has been reported that la(OH)D3 suppresses
proliferation and induces differentiation of Ml
myeloid leukaemia cells in vitro (Abe et al., 1981),
and prolongs the life span of animals inoculated
with them regardless of T-lymphocyte-mediated
immune responses (Honma et al., 1983). However,
no information is available on the effect of
loc(OH)D3 following oral administration on the
growth of metastases except for our previous report
(Sato et al., 1982) and the mechanism of inhibition
of metastasis is not yet evident. Further work will
be necessary to examine whether metastases are
suppressed because lcx(OH)D3 arrests the release of
tumour cells from the primary neoplasm or because
their secondary implantation and development are
impaired.
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